Advertisement


Jonathon Cohen, MD, and Sagar Lonial, MD, on DLBCL: Results of the CALGB/Alliance 50303 Trial

2016 ASH Annual Meeting & Exposition

Advertisement

Jonathon Cohen, MD, and Sagar Lonial, MD, both of Emory University, discuss study findings on R-CHOP vs DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma (Abstract 469).



Related Videos

Leukemia

Jeffrey E. Lancet, MD, on AML: Subgroup Analysis of a Phase III Trial

Jeffrey E. Lancet, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses study findings on survival following allogeneic hematopoietic cell transplantation in older, high-risk acute myeloid leukemia patients initially treated with CPX-351 liposome injection vs standard cytarabine and daunorubicin (Abstract 906).

Leukemia

Harry P. Erba, MD, PhD, on AML: Early Study Results on Vadastuximab Talirine

Harry P. Erba, MD, PhD, of the University of Alabama at Birmingham, discusses phase Ib findings on vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed AML (Abstract 211).

Lymphoma

Syed A. Abutalib, MD, and Alex F. Herrera, MD, on Double-Hit and Double-Expressor Lymphomas: A Retrospective Analysis

Syed A. Abutalib, MD, of Cancer Treatment Centers of America, and Alex F. Herrera, MD, of City of Hope National Medical Center, discuss study findings that suggest allogeneic stem cell transplantation may overcome the chemoresistance of double-hit/double-expressor tumors (Abstract 830).

Leukemia

Martin Schrappe, MD, on Childhood ALL: Study Results on Reducing Treatment Burden

Martin Schrappe, MD, of Christian-Albrechts University Kiel, discusses study findings on reduced intensity delayed intensification in standard-risk patients defined by minimal residual disease in childhood acute lymphoblastic leukemia (Abstract 4).

Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Results of the CheckMate 039 Trial

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses phase I study findings on nivolumab in combination with ipilimumab for relapsed or refractory disease (Abstract 183).

Advertisement

Advertisement




Advertisement